Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo Controlled, Crossover Study to Evaluate the Onset of Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in Allergic Rhinitis Sufferers Following Pollen Exposure in an Environmental Exposure Chamber
Conditions
Interventions
Azelastine hydrochloride (BAYR9258)
Placebo
Locations
1
Canada
Cliantha Research
Mississauga, Ontario, Canada
Start Date
February 3, 2020
Primary Completion Date
March 17, 2021
Completion Date
March 17, 2021
Last Updated
March 25, 2022
NCT07419230
NCT06732414
NCT05494346
NCT07110311
NCT04815668
NCT06846385
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions